MyD88 mediates colorectal cancer cell proliferation, migration and invasion via NF‑κB/AP‑1 signaling pathway

Zhu,Guangwei; Cheng,Zhibin; Huang,Yongjian; Zheng,Wei; Yang,Shugang; Lin,Chunlin; Ye,Jianxin

doi:10.3892/ijmm.2019.4390

MyD88 mediates colorectal cancer cell proliferation, migration and invasion via NF‑κB/AP‑1 signaling pathway

Authors:
- Guangwei Zhu
- Zhibin Cheng
- Yongjian Huang
- Wei Zheng
- Shugang Yang
- Chunlin Lin
- Jianxin Ye
View Affiliations

Affiliations: Department of Gastrointestinal Surgery 2 Section, The First Hospital Affiliated to Fujian Medical University, Fuzhou, Fujian 350005, P.R. China
Published online on: October 31, 2019 https://doi.org/10.3892/ijmm.2019.4390
Pages: 131-140
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The role of myeloid differentiation factor 88 (MyD88) in malignant tumors is largely unknown. Therefore, in this study, we aimed to examine the function and underlying mechanism of MyD88 in colorectal carcinoma in vitro using SW480 and HCT116 cell lines and in vivo using a nude mouse model. SW480 and HCT116 cells were infected with a lentiviral‑based effective MyD88 siRNA virus. CCK‑8 and colony formation assay were used to assess cell proliferation. Transwell and scratch assays were used to test the migration of colorectal cancer cells, and the Transwell assay was further used to analyze the invasiveness of colorectal cancer cells. Western blotting was performed to analyze the underlying mechanism of MyD88 regulation. In vitro experiments demonstrated that silencing MyD88 in SW480 and HCT116 cells markedly suppressed growth and invasion. Furthermore, MyD88 knockdown affected the MyD88‑NF‑κB/AP‑1 signaling pathways in SW480 and HCT116 cells. In vivo, MyD88 knockdown inhibited tumor growth in a HCT116 cell subcutaneous nude model. We found that knockdown of the MyD88 gene can affect proliferation, invasion, and migration of colorectal cancer cells. We further verified that MyD88 knockdown can reduce the activity of NF‑κB and AP‑1 pathways. These results show that MyD88 gene plays an important role in promoting colorectal cancer, and thus can be exploited as a potential diagnostic and prognostic biomarker for colorectal cancer.

View Figures

View References

1	Testa U, Pelosi E and Castelli G: Colorectal cancer: Genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells. Med Sci (Basel). 6:E312018.
2	Okugawa Y, Grady WM and Goel A: Epigenetic alterations in colorectal cancer: Emerging biomarkers. Gastroenterology. 149:1204–1225.e12. 2015. View Article : Google Scholar :
3	Yaghoubi N, Soltani A, Ghazvini K, Hassanian SM and Hashemy SI: PD-1/PD-L1 blockade as a novel treatment for colorectal cancer. Biomed Pharmacother. 110:312–318. 2019. View Article : Google Scholar
4	Marmol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E and Rodriguez Yoldi MJ: Colorectal carcinoma: A general overview and future perspectives in colorectal cancer. Int J Mol Sci. 18:E1972017. View Article : Google Scholar : PubMed/NCBI
5	Lingel A, Ehlers E, Wang Q, Cao M, Wood C, Lin R and Zhang L: Kaposi's sarcoma-associated herpesvirus reduces cellular myeloid differentiation primary-response gene 88 (MyD88) expression via modulation of its RNA. J Virol. 90:180–188. 2016. View Article : Google Scholar :
6	Feng Y, Zou L, Chen C, Li D and Chao W: Role of cardiac- and myeloid-MyD88 signaling in endotoxin shock: A study with tissue-specific deletion models. Anesthesiology. 121:1258–1269. 2014. View Article : Google Scholar : PubMed/NCBI
7	Wang H, Li M, Hung CY, Sinha M, Lee LM, Wiesner DL, LeBert V, Lerksuthirat T, Galles K, Suresh M, et al: MyD88 shapes vaccine immunity by extrinsically regulating survival of CD4⁺ T cells during the contraction phase. PLoS Pathog. 12:e10057872016. View Article : Google Scholar
8	Xu X, Yin Y, Tang J, Xie Y, Han Z, Zhang X, Liu Q, Qin X, Huang X and Sun B: Long non-coding RNA Myd88 promotes growth and metastasis in hepatocellular carcinoma via regulating Myd88 expression through H3K27 modification. Cell Death Dis. 8:e31242017. View Article : Google Scholar : PubMed/NCBI
9	Syeda S, Patel AK, Lee T and Hackam AS: Reduced photoreceptor death and improved retinal function during retinal degeneration in mice lacking innate immunity adaptor protein MyD88. Exp Neurol. 267:1–12. 2015. View Article : Google Scholar : PubMed/NCBI
10	d'Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O'Crowley J, Haley K, Kernan N, Murphy C, Smyth PC, et al: The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer. PLoS One. 9:e1008162014. View Article : Google Scholar : PubMed/NCBI
11	Zhou X, Ramke M, Chintakuntlawar AV, Lee JY, Rajaiya J and Chodosh J: Role of MyD88 in adenovirus keratitis. Immunol Cell Biol. 95:108–116. 2017. View Article : Google Scholar
12	Di Padova F, Quesniaux VFJ and Ryffel B: MyD88 as a therapeutic target for inflammatory lung diseases. Expert Opin Ther Targets. 22:401–408. 2018. View Article : Google Scholar : PubMed/NCBI
13	Reins RY, Courson J, Lema C and Redfern RL: MyD88 contribution to ocular surface homeostasis. PLoS One. 12:e01821532017. View Article : Google Scholar : PubMed/NCBI
14	Zhu G, Zheng W, Huang Y, Hua J, Yang S and Ye J: Expression of MyD88 in cancer tissue of patients with colorectal cancer and clinical significancer. Journal of Jilin University (Medicine Edition). 44:1047–1051. 2018.
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
16	Yan F, Guan J, Peng Y and Zheng X: MyD88 NEDDylation negatively regulates MyD88-dependent NF-κB signaling through antagonizing its ubiquitination. Biochem Biophys Res Commun. 482:632–637. 2017. View Article : Google Scholar
17	Tanishima M, Takashima S, Honda A, Yasuda D, Tanikawa T, Ishii S and MaruYama T: Identification of optineurin as an interleukin-1 receptor-associated kinase 1-binding protein and its role in regulation of MyD88-dependent signaling. J Biol Chem. 292:17250–17257. 2017. View Article : Google Scholar : PubMed/NCBI
18	Wang L, Yu K, Zhang X and Yu S: Dual functional roles of the MyD88 signaling in colorectal cancer development. Biomed Pharmacother. 107:177–184. 2018. View Article : Google Scholar : PubMed/NCBI
19	Klimosch SN, Försti A, Eckert J, Knezevic J, Bevier M, von Schönfels W, Heits N, Walter J, Hinz S, Lascorz J, et al: Functional TLR5 genetic variants affect human colorectal cancer survival. Cancer Res. 73:7232–7242. 2013. View Article : Google Scholar : PubMed/NCBI
20	Ikebe M, Kitaura Y, Nakamura M, Tanaka H, Yamasaki A, Nagai S, Wada J, Yanai K, Koga K, Sato N, et al: Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathway. J Surg Oncol. 100:725–731. 2009. View Article : Google Scholar : PubMed/NCBI
21	Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, Kudo E, Shimada M and Sano T: High expression of toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer. 102:908–915. 2010. View Article : Google Scholar : PubMed/NCBI
22	Rakoff-Nahoum S and Medzhitov R: Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science. 317:124–127. 2007. View Article : Google Scholar : PubMed/NCBI
23	Chang CM, Chia VM, Gunter MJ, Zanetti KA, Ryan BM, Goodman JE, Harris CC, Weissfeld J, Huang WY, Chanock S, et al: Innate immunity gene polymorphisms and the risk of colorectal neoplasia. Carcinogenesis. 34:2512–2520. 2013. View Article : Google Scholar : PubMed/NCBI
24	Schiechl G, Bauer B, Fuss I, Lang SA, Moser C, Ruemmele P, Rose-John S, Neurath MF, Geissler EK, Schlitt HJ, et al: Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80⁺CD11b(high)Gr1(low) macrophages. J Clin Invest. 121:1692–1708. 2011. View Article : Google Scholar : PubMed/NCBI
25	Galardi S, Mercatelli N, Farace MG and Ciafre SA: NF-κB and c-Jun induce the expression of the oncogenic miR-221 and miR-222 in prostate carcinoma and glioblastoma cells. Nucleic Acids Res. 39:3892–3902. 2011. View Article : Google Scholar : PubMed/NCBI
26	Chen X, Yang X, Liu T, Guan M, Feng X, Dong W, Chu X, Liu J, Tian X, Ci X, et al: Kaempferol regulates MAPKs and NF-κB signaling pathways to attenuate LPS-induced acute lung injury in mice. Int Immunopharmacol. 14:209–216. 2012. View Article : Google Scholar : PubMed/NCBI
27	Park JW, Yoon HJ, Kang WY, Cho S, Seong SJ, Lee HW, Yoon YR and Kim HJ: G protein-coupled receptor 84 controls osteoclastogenesis through inhibition of NF-κB and MAPK signaling pathways. J Cell Physiol. 233:1481–1489. 2018. View Article : Google Scholar
28	Zheng Y, Fang W, Fan S, Liao W, Xiong Y, Liao S, Li Y, Xiao S and Liu J: Neurotropin inhibits neuroinflammation via suppressing NF-κB and MAPKs signaling pathways in lipopoly-saccharide-stimulated BV2 cells. J Pharmacol Sci. 136:242–248. 2018. View Article : Google Scholar : PubMed/NCBI
29	Pan JX: LncRNA H19 promotes atherosclerosis by regulating MAPK and NF-κB signaling pathway. Eur Rev Med Pharmacol Sci. 21:322–328. 2017.PubMed/NCBI
30	Parola C, Salogni L, Vaira X, Scutera S, Somma P, Salvi V, Musso T, Tabbia G, Bardessono M, Pasquali C, et al: Selective activation of human dendritic cells by OM-85 through a NF-κB and MAPK dependent pathway. PLoS One. 8:e828672013. View Article : Google Scholar